You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameThiamylal
Accession NumberDB01154  (APRD00154)
TypeSmall Molecule
GroupsApproved, Vet Approved
DescriptionA barbiturate that is administered intravenously for the production of complete anesthesia of short duration, for the induction of general anesthesia, or for inducing a hypnotic state. (From Martindale, The Extra Pharmacopoeia, 30th ed, p919)
Structure
Thumb
Synonyms
5-Allyl-5-(1-methylbutyl)-2-thiobarbituric acid
5-Allyl-5-(1-methylbutyl)-2-thioxodihydro-4,6(1H,5H)-pyrimidinedione
5-Allyl-5-(1-methylbutyl)-2-thioxodihydropyrimidine-4,6(1H,5H)-dione
dihydro-5-(1-Methylbutyl)-5-(2-propenyl)-2-thioxo-4,6(1H,5H)-pyrimidinedione
Thiamylal
Thioseconal
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
SuritalNot Available
ThioseconalNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Thiamylal sodium
ThumbNot applicableDBSALT001404
Categories
UNII01T23W89FR
CAS number77-27-0
WeightAverage: 254.349
Monoisotopic: 254.10889852
Chemical FormulaC12H18N2O2S
InChI KeyXLOMZPUITCYLMJ-UHFFFAOYSA-N
InChI
InChI=1S/C12H18N2O2S/c1-4-6-8(3)12(7-5-2)9(15)13-11(17)14-10(12)16/h5,8H,2,4,6-7H2,1,3H3,(H2,13,14,15,16,17)
IUPAC Name
5-(pentan-2-yl)-5-(prop-2-en-1-yl)-2-sulfanylidene-1,3-diazinane-4,6-dione
SMILES
CCCC(C)C1(CC=C)C(=O)NC(=S)NC1=O
Pharmacology
IndicationUsed for the production of complete anaesthesia of short duration, for the induction of general anaesthesia, and for inducing a hypnotic state.
Structured Indications Not Available
PharmacodynamicsThiamylal, a barbiturate, is used in combination with acetaminophen or aspirin and caffeine for its sedative and relaxant effects in the treatment of tension headaches, migraines, and pain. Barbiturates act as nonselective depressants of the central nervous system (CNS), capable of producing all levels of CNS mood alteration from excitation to mild sedation, hypnosis, and deep coma. In sufficiently high therapeutic doses, barbiturates induce anesthesia.
Mechanism of actionThiamylal binds at a distinct binding site associated with a Cl- ionopore at the GABAA receptor, increasing the duration of time for which the Cl- ionopore is open. The post-synaptic inhibitory effect of GABA in the thalamus is, therefore, prolonged.
TargetKindPharmacological actionActionsOrganismUniProt ID
Gamma-aminobutyric acid receptor subunit alpha-1Proteinyes
agonist
HumanP14867 details
ATP-sensitive inward rectifier potassium channel 8Proteinyes
inhibitor
HumanQ15842 details
ATP-sensitive inward rectifier potassium channel 11Proteinyes
inhibitor
HumanQ14654 details
Related Articles
AbsorptionRapidly absorbed (high lipid solubility).
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Hepatic.

Route of eliminationNot Available
Half lifeAlthough no studies have been performed on humans, the half-life in cats is 14.3 hours.
ClearanceNot Available
ToxicityIntravenous LD50 in rat is 51 mg/kg.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when Thiamylal is combined with 1,1,1,2 Tetrafluoroethane.Investigational
7-NitroindazoleThe risk or severity of adverse effects can be increased when Thiamylal is combined with 7-Nitroindazole.Experimental
AbirateroneThe metabolism of Thiamylal can be decreased when combined with Abiraterone.Approved
AcebutololThiamylal may increase the hypotensive activities of Acebutolol.Approved
AcenocoumarolThe metabolism of Acenocoumarol can be increased when combined with Thiamylal.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Aceprometazine.Approved
AcetaminophenThe metabolism of Acetaminophen can be increased when combined with Thiamylal.Approved
AcetazolamideThiamylal may increase the hypotensive activities of Acetazolamide.Approved, Vet Approved
adipiplonThe risk or severity of adverse effects can be increased when Thiamylal is combined with adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Agomelatine.Approved, Investigational
AldesleukinThiamylal may increase the hypotensive activities of Aldesleukin.Approved
AlfaxaloneThe risk or severity of adverse effects can be increased when Thiamylal is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Thiamylal.Approved, Illicit
AliskirenThiamylal may increase the hypotensive activities of Aliskiren.Approved, Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Thiamylal is combined with Alphacetylmethadol.Experimental, Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Thiamylal.Approved, Illicit, Investigational
AlprenololThe serum concentration of Alprenolol can be decreased when it is combined with Thiamylal.Approved, Withdrawn
Ambroxol acefyllinateThe serum concentration of Ambroxol acefyllinate can be decreased when it is combined with Thiamylal.Experimental
AmifostineThiamylal may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideThiamylal may increase the hypotensive activities of Amiloride.Approved
AmineptineThe metabolism of Amineptine can be increased when combined with Thiamylal.Illicit, Withdrawn
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Thiamylal.Approved
AmiodaroneThe metabolism of Thiamylal can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Thiamylal is combined with Amisulpride.Approved, Investigational
AmitriptylineThe metabolism of Amitriptyline can be increased when combined with Thiamylal.Approved
AmlodipineThiamylal may increase the hypotensive activities of Amlodipine.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Amobarbital.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Thiamylal is combined with Amperozide.Experimental
Amphotericin BThiamylal may increase the hypotensive activities of Amphotericin B.Approved, Investigational
AmrinoneThe metabolism of Amrinone can be increased when combined with Thiamylal.Approved
Amyl NitriteThiamylal may increase the hypotensive activities of Amyl Nitrite.Approved
Aop200704The serum concentration of Aop200704 can be decreased when it is combined with Thiamylal.Investigational
ApomorphineThiamylal may increase the hypotensive activities of Apomorphine.Approved, Investigational
ApraclonidineThiamylal may increase the hypotensive activities of Apraclonidine.Approved
AprepitantThe metabolism of Thiamylal can be increased when combined with Aprepitant.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Thiamylal is combined with Aripiprazole.Approved, Investigational
ArotinololThe serum concentration of Arotinolol can be decreased when it is combined with Thiamylal.Approved
Arsenic trioxideThiamylal may increase the hypotensive activities of Arsenic trioxide.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Asenapine.Approved
AtenololThiamylal may increase the hypotensive activities of Atenolol.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Thiamylal is combined with Azaperone.Vet Approved
AzelastineThiamylal may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Azelastine.Approved
AzelnidipineThe metabolism of Azelnidipine can be increased when combined with Thiamylal.Approved
Azilsartan medoxomilThiamylal may increase the hypotensive activities of Azilsartan medoxomil.Approved
AzimilideThe metabolism of Azimilide can be increased when combined with Thiamylal.Investigational
BaclofenThe risk or severity of adverse effects can be increased when Thiamylal is combined with Baclofen.Approved
BarbitalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Barbital.Illicit
BarnidipineThe metabolism of Barnidipine can be increased when combined with Thiamylal.Approved
BefunololThe serum concentration of Befunolol can be decreased when it is combined with Thiamylal.Experimental
BenazeprilThiamylal may increase the hypotensive activities of Benazepril.Approved, Investigational
BendroflumethiazideThiamylal may increase the orthostatic hypotensive activities of Bendroflumethiazide.Approved
BenidipineThe metabolism of Benidipine can be increased when combined with Thiamylal.Approved
BenperidolThe risk or severity of adverse effects can be increased when Thiamylal is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Thiamylal.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Thiamylal is combined with Benzyl alcohol.Approved
BepridilThe metabolism of Bepridil can be increased when combined with Thiamylal.Approved, Withdrawn
BetaxololThiamylal may increase the hypotensive activities of Betaxolol.Approved
BevantololThe serum concentration of Bevantolol can be decreased when it is combined with Thiamylal.Approved
BisoprololThiamylal may increase the hypotensive activities of Bisoprolol.Approved
BopindololThe serum concentration of Bopindolol can be decreased when it is combined with Thiamylal.Approved
BortezomibThiamylal may increase the hypotensive activities of Bortezomib.Approved, Investigational
BretyliumThiamylal may increase the hypotensive activities of Bretylium.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Thiamylal is combined with Brexpiprazole.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Brimonidine.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Thiamylal.Approved
BromazepamThe risk or severity of adverse effects can be increased when Thiamylal is combined with Bromazepam.Approved, Illicit
BromocriptineThiamylal may increase the hypotensive activities of Bromocriptine.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Thiamylal is combined with Brotizolam.Approved, Withdrawn
BucindololThe serum concentration of Bucindolol can be decreased when it is combined with Thiamylal.Investigational
BufuralolThe serum concentration of Bufuralol can be decreased when it is combined with Thiamylal.Experimental, Investigational
BumetanideThiamylal may increase the hypotensive activities of Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Thiamylal.Approved, Investigational
BupranololThe serum concentration of Bupranolol can be decreased when it is combined with Thiamylal.Approved
BuprenorphineThiamylal may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Thiamylal.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Thiamylal.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Thiamylal is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Thiamylal.Approved, Illicit, Vet Approved
CaiThe metabolism of Cai can be increased when combined with Thiamylal.Investigational
CanagliflozinThiamylal may increase the hypotensive activities of Canagliflozin.Approved
CandesartanThiamylal may increase the hypotensive activities of Candesartan.Approved
CapecitabineThe metabolism of Thiamylal can be decreased when combined with Capecitabine.Approved, Investigational
CaptoprilThiamylal may increase the hypotensive activities of Captopril.Approved
CarbamazepineThe metabolism of Thiamylal can be increased when combined with Carbamazepine.Approved, Investigational
CarbetocinThiamylal may increase the hypotensive activities of Carbetocin.Approved
CarbinoxamineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Thiamylal is combined with Carfentanil.Illicit, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Thiamylal is combined with Carisoprodol.Approved
CarteololThiamylal may increase the hypotensive activities of Carteolol.Approved
CarvedilolThiamylal may increase the hypotensive activities of Carvedilol.Approved, Investigational
CeliprololThe serum concentration of Celiprolol can be decreased when it is combined with Thiamylal.Approved, Investigational
CeritinibThe serum concentration of Thiamylal can be increased when it is combined with Ceritinib.Approved
CetirizineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Thiamylal is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChloramphenicolThe metabolism of Thiamylal can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Thiamylal.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Thiamylal is combined with Chlormezanone.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Chloroprocaine.Approved
ChlorothiazideThiamylal may increase the orthostatic hypotensive activities of Chlorothiazide.Approved, Vet Approved
ChlorotrianiseneThe therapeutic efficacy of Chlorotrianisene can be decreased when used in combination with Thiamylal.Withdrawn
ChlorphenamineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Chlorphenamine.Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Thiamylal.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Thiamylal is combined with Chlorprothixene.Approved, Withdrawn
ChlorthalidoneThiamylal may increase the orthostatic hypotensive activities of Chlorthalidone.Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Thiamylal is combined with Chlorzoxazone.Approved
CholecalciferolThe metabolism of Thiamylal can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CilazaprilThiamylal may increase the hypotensive activities of Cilazapril.Approved
CilnidipineThe metabolism of Cilnidipine can be increased when combined with Thiamylal.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Thiamylal.Approved, Vet Approved
CinnarizineThe metabolism of Cinnarizine can be increased when combined with Thiamylal.Approved
CitalopramThe risk or severity of adverse effects can be increased when Thiamylal is combined with Citalopram.Approved
ClemastineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Clemastine.Approved
ClevidipineThiamylal may increase the hypotensive activities of Clevidipine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Thiamylal is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Thiamylal is combined with Clobazam.Approved, Illicit
ClofarabineThiamylal may increase the hypotensive activities of Clofarabine.Approved, Investigational
clomethiazoleThe risk or severity of adverse effects can be increased when Thiamylal is combined with clomethiazole.Investigational
ClomipramineThe metabolism of Clomipramine can be increased when combined with Thiamylal.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Thiamylal is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Clonidine.Approved
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Thiamylal.Approved, Illicit
ClotrimazoleThe metabolism of Thiamylal can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Thiamylal.Approved
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Thiamylal.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Thiamylal.Approved, Illicit
ConivaptanThiamylal may increase the hypotensive activities of Conivaptan.Approved, Investigational
Conjugated Equine EstrogensThe therapeutic efficacy of Conjugated Equine Estrogens can be decreased when used in combination with Thiamylal.Approved
CyclizineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Cyclizine.Approved
CyclobenzaprineThe metabolism of Cyclobenzaprine can be increased when combined with Thiamylal.Approved
CyclosporineThe metabolism of Cyclosporine can be increased when combined with Thiamylal.Approved, Investigational, Vet Approved
CyclosporineThe metabolism of Thiamylal can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Cyproheptadine.Approved
DabrafenibThe serum concentration of Thiamylal can be decreased when it is combined with Dabrafenib.Approved
DantroleneThe risk or severity of adverse effects can be increased when Thiamylal is combined with Dantrolene.Approved
DapagliflozinThiamylal may increase the hypotensive activities of Dapagliflozin.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Thiamylal.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Dapoxetine.Investigational
DarodipineThe metabolism of Darodipine can be increased when combined with Thiamylal.Experimental
DelavirdineThe metabolism of Thiamylal can be decreased when combined with Delavirdine.Approved
deramciclaneThe risk or severity of adverse effects can be increased when Thiamylal is combined with deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Thiamylal is combined with Desflurane.Approved
DesipramineThe metabolism of Desipramine can be increased when combined with Thiamylal.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Desloratadine.Approved, Investigational
DesogestrelThe therapeutic efficacy of Desogestrel can be decreased when used in combination with Thiamylal.Approved
DesvenlafaxineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Thiamylal.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Thiamylal is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Thiamylal.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Dezocine.Approved
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Thiamylal.Approved, Illicit, Vet Approved
DiclofenamideThiamylal may increase the hypotensive activities of Diclofenamide.Approved
DicoumarolThe metabolism of Dicoumarol can be increased when combined with Thiamylal.Approved
DienestrolThe therapeutic efficacy of Dienestrol can be decreased when used in combination with Thiamylal.Approved
DienogestThe therapeutic efficacy of Dienogest can be decreased when used in combination with Thiamylal.Approved
DiethylstilbestrolThe therapeutic efficacy of Diethylstilbestrol can be decreased when used in combination with Thiamylal.Approved
DifenoxinThe risk or severity of adverse effects can be increased when Thiamylal is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Dihydrocodeine.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Dihydromorphine.Experimental, Illicit
DiltiazemThiamylal may increase the hypotensive activities of Diltiazem.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Thiamylal is combined with Dimenhydrinate.Approved
DinutuximabThiamylal may increase the hypotensive activities of Dinutuximab.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Thiamylal.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Thiamylal.Approved, Illicit
DipyridamoleThiamylal may increase the hypotensive activities of Dipyridamole.Approved
DoramectinThe risk or severity of adverse effects can be increased when Thiamylal is combined with Doramectin.Vet Approved
DosulepinThe metabolism of Dosulepin can be increased when combined with Thiamylal.Approved
DotarizineThe metabolism of Dotarizine can be increased when combined with Thiamylal.Investigational
DoxazosinThiamylal may increase the hypotensive activities of Doxazosin.Approved
DoxepinThe metabolism of Doxepin can be increased when combined with Thiamylal.Approved
DoxycyclineThe serum concentration of Doxycycline can be decreased when it is combined with Thiamylal.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Thiamylal.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Thiamylal is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Thiamylal.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Thiamylal.Approved, Vet Approved
DrospirenoneThe therapeutic efficacy of Drospirenone can be decreased when used in combination with Thiamylal.Approved
DrotebanolThe risk or severity of adverse effects can be increased when Thiamylal is combined with Drotebanol.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Thiamylal.Approved
DyphyllineThe serum concentration of Dyphylline can be decreased when it is combined with Thiamylal.Approved
EcgonineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Ecgonine.Experimental, Illicit
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Thiamylal is combined with ECGONINE METHYL ESTER.Experimental
EcopipamThe risk or severity of adverse effects can be increased when Thiamylal is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Thiamylal is combined with Efavirenz.Approved, Investigational
EfonidipineThe metabolism of Efonidipine can be increased when combined with Thiamylal.Approved
EmpagliflozinThiamylal may increase the hypotensive activities of Empagliflozin.Approved
EnalaprilThiamylal may increase the hypotensive activities of Enalapril.Approved, Vet Approved
EnalaprilatThiamylal may increase the hypotensive activities of Enalaprilat.Approved
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Thiamylal.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Thiamylal is combined with Entacapone.Approved, Investigational
EperisoneThe metabolism of Eperisone can be increased when combined with Thiamylal.Approved, Investigational
EplerenoneThiamylal may increase the hypotensive activities of Eplerenone.Approved
EpoprostenolThiamylal may increase the hypotensive activities of Epoprostenol.Approved
EprosartanThiamylal may increase the hypotensive activities of Eprosartan.Approved
EscitalopramThe risk or severity of adverse effects can be increased when Thiamylal is combined with Escitalopram.Approved, Investigational
EsmirtazapineThe metabolism of Esmirtazapine can be increased when combined with Thiamylal.Investigational
EsmololThiamylal may increase the hypotensive activities of Esmolol.Approved
EstazolamThe risk or severity of adverse effects can be increased when Thiamylal is combined with Estazolam.Approved, Illicit
EstradiolThe therapeutic efficacy of Estradiol can be decreased when used in combination with Thiamylal.Approved, Investigational, Vet Approved
EstramustineThe therapeutic efficacy of Estramustine can be decreased when used in combination with Thiamylal.Approved
Estrogens, esterifiedThe therapeutic efficacy of Estrogens, esterified can be decreased when used in combination with Thiamylal.Approved
Estrone sulfateThe therapeutic efficacy of Estrone sulfate can be decreased when used in combination with Thiamylal.Approved
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Thiamylal.Approved
Etacrynic acidThiamylal may increase the hypotensive activities of Etacrynic acid.Approved
EthanolThiamylal may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Thiamylal.Approved, Illicit, Withdrawn
Ethinyl EstradiolThe therapeutic efficacy of Ethinyl Estradiol can be decreased when used in combination with Thiamylal.Approved
EthosuximideThe risk or severity of adverse effects can be increased when Thiamylal is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Thiamylal is combined with Ethotoin.Approved
Ethyl biscoumacetateThe metabolism of Ethyl biscoumacetate can be increased when combined with Thiamylal.Withdrawn
Ethyl carbamateThe risk or severity of adverse effects can be increased when Thiamylal is combined with Ethyl carbamate.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Thiamylal is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Ethylmorphine.Approved, Illicit
Ethynodiol diacetateThe therapeutic efficacy of Ethynodiol diacetate can be decreased when used in combination with Thiamylal.Approved
EtidocaineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Etifoxine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Thiamylal is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Thiamylal.Approved
EtonogestrelThe therapeutic efficacy of Etonogestrel can be decreased when used in combination with Thiamylal.Approved, Investigational
EtoperidoneThe risk or severity of adverse effects can be increased when Thiamylal is combined with Etoperidone.Approved
EtorphineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Etorphine.Illicit, Vet Approved
EtravirineThe metabolism of Thiamylal can be decreased when combined with Etravirine.Approved
EzogabineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Ezogabine.Approved
FelbamateThe serum concentration of Thiamylal can be increased when it is combined with Felbamate.Approved
FelodipineThiamylal may increase the hypotensive activities of Felodipine.Approved, Investigational
FencamfamineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Fencamfamine.Approved, Illicit, Withdrawn
FendilineThe metabolism of Fendiline can be increased when combined with Thiamylal.Withdrawn
FenoldopamThiamylal may increase the hypotensive activities of Fenoldopam.Approved
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Thiamylal.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Fexofenadine.Approved
FimasartanThiamylal may increase the hypotensive activities of Fimasartan.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Thiamylal is combined with Flibanserin.Approved
FloxuridineThe metabolism of Thiamylal can be decreased when combined with Floxuridine.Approved
FluconazoleThe metabolism of Thiamylal can be decreased when combined with Fluconazole.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Thiamylal is combined with Fludiazepam.Approved, Illicit
FluindioneThe metabolism of Fluindione can be increased when combined with Thiamylal.Investigational
FlunarizineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Thiamylal is combined with Flunitrazepam.Approved, Illicit
FluorouracilThe metabolism of Thiamylal can be decreased when combined with Fluorouracil.Approved
FluoxetineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Thiamylal.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Thiamylal.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Thiamylal.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Thiamylal is combined with Fluspirilene.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Thiamylal is combined with Fluticasone Propionate.Approved
FluvastatinThe metabolism of Thiamylal can be decreased when combined with Fluvastatin.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Thiamylal.Approved, Investigational
FosinoprilThiamylal may increase the hypotensive activities of Fosinopril.Approved
FosphenytoinThe metabolism of Thiamylal can be increased when combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Thiamylal is combined with Fospropofol.Approved, Illicit
FurosemideThiamylal may increase the hypotensive activities of Furosemide.Approved, Vet Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Thiamylal.Approved, Investigational
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Thiamylal is combined with gabapentin enacarbil.Approved
GallopamilThe metabolism of Gallopamil can be increased when combined with Thiamylal.Investigational
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Thiamylal is combined with Gamma Hydroxybutyric Acid.Approved, Illicit
GemfibrozilThe metabolism of Thiamylal can be decreased when combined with Gemfibrozil.Approved
GepironeThe risk or severity of adverse effects can be increased when Thiamylal is combined with Gepirone.Investigational
GestodeneThe therapeutic efficacy of Gestodene can be decreased when used in combination with Thiamylal.Approved
GlutethimideThe risk or severity of adverse effects can be increased when Thiamylal is combined with Glutethimide.Approved, Illicit
GriseofulvinThe serum concentration of Griseofulvin can be decreased when it is combined with Thiamylal.Approved, Vet Approved
GuanfacineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Thiamylal.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Thiamylal.Approved
HalothaneThe risk or severity of adverse effects can be increased when Thiamylal is combined with Halothane.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Thiamylal is combined with Heroin.Approved, Illicit
HexestrolThe therapeutic efficacy of Hexestrol can be decreased when used in combination with Thiamylal.Withdrawn
HexobarbitalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Hexobarbital.Approved
HydralazineThiamylal may increase the hypotensive activities of Hydralazine.Approved
HydrochlorothiazideThiamylal may increase the orthostatic hypotensive activities of Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneThiamylal may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydroflumethiazideThiamylal may increase the orthostatic hypotensive activities of Hydroflumethiazide.Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Thiamylal.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Thiamylal.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Thiamylal is combined with Iloperidone.Approved
IloprostThiamylal may increase the hypotensive activities of Iloprost.Approved, Investigational
ImidaprilThiamylal may increase the hypotensive activities of Imidapril.Investigational
ImipramineThe metabolism of Imipramine can be increased when combined with Thiamylal.Approved
IndalpineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Indalpine.Investigational, Withdrawn
IndapamideThiamylal may increase the orthostatic hypotensive activities of Indapamide.Approved
IndenololThe serum concentration of Indenolol can be decreased when it is combined with Thiamylal.Withdrawn
IndinavirThe metabolism of Thiamylal can be decreased when combined with Indinavir.Approved
IndoraminThiamylal may increase the hypotensive activities of Indoramin.Withdrawn
IrbesartanThe metabolism of Thiamylal can be decreased when combined with Irbesartan.Approved, Investigational
IsocarboxazidThiamylal may increase the hypotensive activities of Isocarboxazid.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Thiamylal.Approved, Vet Approved
Isosorbide DinitrateThiamylal may increase the hypotensive activities of Isosorbide Dinitrate.Approved
Isosorbide MononitrateThiamylal may increase the hypotensive activities of Isosorbide Mononitrate.Approved
IsoxsuprineThiamylal may increase the hypotensive activities of Isoxsuprine.Approved, Withdrawn
IsradipineThiamylal may increase the hypotensive activities of Isradipine.Approved
KetamineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Ketamine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Thiamylal is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Thiamylal is combined with Ketobemidone.Approved
KetoconazoleThe metabolism of Thiamylal can be decreased when combined with Ketoconazole.Approved, Investigational
LabetalolThiamylal may increase the hypotensive activities of Labetalol.Approved
LacidipineThe metabolism of Lacidipine can be increased when combined with Thiamylal.Approved
LamotrigineThe serum concentration of Lamotrigine can be decreased when it is combined with Thiamylal.Approved, Investigational
LeflunomideThe metabolism of Thiamylal can be decreased when combined with Leflunomide.Approved, Investigational
LercanidipineThe metabolism of Lercanidipine can be increased when combined with Thiamylal.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Thiamylal is combined with Levetiracetam.Approved, Investigational
LevobunololThiamylal may increase the hypotensive activities of Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Thiamylal.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Thiamylal is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Thiamylal is combined with Levomethadyl Acetate.Approved
LevomilnacipranThe risk or severity of adverse effects can be increased when Thiamylal is combined with Levomilnacipran.Approved
LevonorgestrelThe therapeutic efficacy of Levonorgestrel can be decreased when used in combination with Thiamylal.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Thiamylal.Approved
LevosimendanThiamylal may increase the hypotensive activities of Levosimendan.Approved, Investigational
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Thiamylal.Approved, Vet Approved
LisinoprilThiamylal may increase the hypotensive activities of Lisinopril.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Thiamylal is combined with Lithium.Approved
LofentanilThe risk or severity of adverse effects can be increased when Thiamylal is combined with Lofentanil.Illicit
LofexidineThiamylal may increase the hypotensive activities of Lofexidine.Approved, Investigational
LoratadineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Thiamylal.Approved
LosartanThe metabolism of Thiamylal can be decreased when combined with Losartan.Approved
LovastatinThe metabolism of Thiamylal can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Thiamylal.Approved
Lu AA21004The risk or severity of adverse effects can be increased when Thiamylal is combined with Lu AA21004.Investigational
LumacaftorThe serum concentration of Thiamylal can be decreased when it is combined with Lumacaftor.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Thiamylal is combined with Lurasidone.Approved
LynestrenolThe therapeutic efficacy of Lynestrenol can be decreased when used in combination with Thiamylal.Investigational
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Thiamylal.Approved, Vet Approved
ManidipineThe metabolism of Manidipine can be increased when combined with Thiamylal.Approved
MannitolThiamylal may increase the hypotensive activities of Mannitol.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Maprotiline.Approved
MecamylamineThiamylal may increase the hypotensive activities of Mecamylamine.Approved
MeclizineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Meclizine.Approved
MedetomidineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Medetomidine.Vet Approved
Medroxyprogesterone acetateThe therapeutic efficacy of Medroxyprogesterone acetate can be decreased when used in combination with Thiamylal.Approved, Investigational
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Thiamylal.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Thiamylal is combined with Melperone.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Thiamylal.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Thiamylal.Approved, Illicit
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Thiamylal.Approved
MestranolThe therapeutic efficacy of Mestranol can be decreased when used in combination with Thiamylal.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Thiamylal is combined with Metaxalone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Thiamylal.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Thiamylal is combined with Methadyl Acetate.Approved, Illicit
MethallenestrilThe therapeutic efficacy of Methallenestril can be decreased when used in combination with Thiamylal.Experimental
MethapyrileneThe risk or severity of adverse effects can be increased when Thiamylal is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Thiamylal is combined with Methaqualone.Illicit, Withdrawn
MethazolamideThiamylal may increase the hypotensive activities of Methazolamide.Approved
MethocarbamolThe risk or severity of adverse effects can be increased when Thiamylal is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Thiamylal.Approved
MethotrimeprazineThiamylal may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Thiamylal.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Thiamylal is combined with Methsuximide.Approved
MethyclothiazideThiamylal may increase the orthostatic hypotensive activities of Methyclothiazide.Approved
MethyldopaThiamylal may increase the hypotensive activities of Methyldopa.Approved
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Thiamylal.Approved
MetipranololThiamylal may increase the hypotensive activities of Metipranolol.Approved
MetolazoneThiamylal may increase the orthostatic hypotensive activities of Metolazone.Approved
MetoprololThiamylal may increase the hypotensive activities of Metoprolol.Approved, Investigational
MetyrosineThiamylal may increase the sedative activities of Metyrosine.Approved
MianserinMianserin may increase the central nervous system depressant (CNS depressant) activities of Thiamylal.Approved
MibefradilThe metabolism of Mibefradil can be increased when combined with Thiamylal.Withdrawn
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Thiamylal.Approved, Illicit
MifepristoneThe serum concentration of Thiamylal can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Thiamylal is combined with Milnacipran.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Thiamylal.Approved, Investigational
MinoxidilThiamylal may increase the hypotensive activities of Minoxidil.Approved
MirtazapineThiamylal may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MoexiprilThiamylal may increase the hypotensive activities of Moexipril.Approved
MolindoneThe risk or severity of adverse effects can be increased when Thiamylal is combined with Molindone.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Thiamylal.Approved, Investigational
MoxonidineThiamylal may increase the hypotensive activities of Moxonidine.Approved
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Thiamylal.Approved, Investigational
NadololThiamylal may increase the hypotensive activities of Nadolol.Approved
NaftopidilThe metabolism of Naftopidil can be increased when combined with Thiamylal.Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Thiamylal.Approved
NebivololThiamylal may increase the hypotensive activities of Nebivolol.Approved, Investigational
NefazodoneThe risk or severity of adverse effects can be increased when Thiamylal is combined with Nefazodone.Approved, Withdrawn
NesiritideThiamylal may increase the hypotensive activities of Nesiritide.Approved, Investigational
NicardipineThe metabolism of Thiamylal can be decreased when combined with Nicardipine.Approved
NifedipineThiamylal may increase the hypotensive activities of Nifedipine.Approved
NiguldipineThe metabolism of Niguldipine can be increased when combined with Thiamylal.Experimental
NiludipineThe metabolism of Niludipine can be increased when combined with Thiamylal.Experimental
NilvadipineThe metabolism of Nilvadipine can be increased when combined with Thiamylal.Approved
NimesulideThe metabolism of Nimesulide can be increased when combined with Thiamylal.Approved, Withdrawn
NimodipineThiamylal may increase the hypotensive activities of Nimodipine.Approved
NisoldipineThiamylal may increase the hypotensive activities of Nisoldipine.Approved
NitrazepamThe risk or severity of adverse effects can be increased when Thiamylal is combined with Nitrazepam.Approved
NitrendipineThe metabolism of Nitrendipine can be increased when combined with Thiamylal.Approved
Nitric OxideThiamylal may increase the hypotensive activities of Nitric Oxide.Approved
NitroglycerinThiamylal may increase the hypotensive activities of Nitroglycerin.Approved, Investigational
NitroprussideThiamylal may increase the hypotensive activities of Nitroprusside.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Thiamylal is combined with Nitrous oxide.Approved, Vet Approved
NorelgestrominThe therapeutic efficacy of Norelgestromin can be decreased when used in combination with Thiamylal.Approved
NorgestimateThe therapeutic efficacy of Norgestimate can be decreased when used in combination with Thiamylal.Approved
NorgestrelThe therapeutic efficacy of Norgestrel can be decreased when used in combination with Thiamylal.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Thiamylal is combined with Normethadone.Approved, Illicit
NortriptylineThe metabolism of Nortriptyline can be increased when combined with Thiamylal.Approved
ObinutuzumabThiamylal may increase the hypotensive activities of Obinutuzumab.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Thiamylal.Approved, Investigational
OlmesartanThiamylal may increase the hypotensive activities of Olmesartan.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Olopatadine.Approved
OmeprazoleThe metabolism of Thiamylal can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Thiamylal.Approved
OpipramolThe metabolism of Opipramol can be increased when combined with Thiamylal.Investigational
OpiumThe risk or severity of adverse effects can be increased when Thiamylal is combined with Opium.Approved, Illicit
OrphenadrineThiamylal may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Thiamylal is combined with Osanetant.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Thiamylal.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Oxetacaine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Thiamylal is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Thiamylal.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Thiamylal.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Thiamylal is combined with Oxymorphone.Approved, Investigational, Vet Approved
PaclitaxelThiamylal may increase the hypotensive activities of Paclitaxel.Approved, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Thiamylal is combined with Paliperidone.Approved
PapaverineThiamylal may increase the hypotensive activities of Papaverine.Approved
ParaldehydeThiamylal may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Paroxetine.Approved, Investigational
PenbutololThiamylal may increase the hypotensive activities of Penbutolol.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Thiamylal.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Thiamylal.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Thiamylal.Approved
PerazineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Perazine.Investigational
PerhexilineThe metabolism of Perhexiline can be increased when combined with Thiamylal.Approved
PerindoprilThiamylal may increase the hypotensive activities of Perindopril.Approved
PerospironeThe risk or severity of adverse effects can be increased when Thiamylal is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Thiamylal.Approved
PethidineThiamylal may increase the central nervous system depressant (CNS depressant) activities of Pethidine.Approved
PhenelzineThiamylal may increase the hypotensive activities of Phenelzine.Approved
PhenindioneThe metabolism of Phenindione can be increased when combined with Thiamylal.Approved
PhenobarbitalThe metabolism of Thiamylal can be increased when combined with Phenobarbital.Approved
PhenoxybenzamineThiamylal may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Thiamylal is combined with Phenoxyethanol.Approved
PhenprocoumonThe metabolism of Phenprocoumon can be increased when combined with Thiamylal.Approved
PhentolamineThiamylal may increase the hypotensive activities of Phentolamine.Approved
PhenytoinThe metabolism of Thiamylal can be increased when combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Thiamylal.Approved
PinaveriumThe metabolism of Pinaverium can be increased when combined with Thiamylal.Approved
PindololThiamylal may increase the hypotensive activities of Pindolol.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Thiamylal is combined with Pipamperone.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Pipotiazine.Approved
PiritramideThe risk or severity of adverse effects can be increased when Thiamylal is combined with Piritramide.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Thiamylal is combined with Pizotifen.Approved
PolythiazideThiamylal may increase the orthostatic hypotensive activities of Polythiazide.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Thiamylal is combined with Pomalidomide.Approved
PractololThe serum concentration of Practolol can be decreased when it is combined with Thiamylal.Approved
PramipexoleThiamylal may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Thiamylal is combined with Prazepam.Approved, Illicit
PrazosinThiamylal may increase the hypotensive activities of Prazosin.Approved
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Thiamylal.Approved, Illicit, Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when Thiamylal is combined with Pregnanolone.Investigational
PrenylamineThe metabolism of Prenylamine can be increased when combined with Thiamylal.Withdrawn
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Thiamylal.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Primidone is combined with Thiamylal.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Thiamylal.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Thiamylal.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Thiamylal.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Promethazine.Approved
PropacetamolThe metabolism of Propacetamol can be increased when combined with Thiamylal.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Thiamylal.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Thiamylal.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Propoxycaine.Approved
PropranololThiamylal may increase the hypotensive activities of Propranolol.Approved, Investigational
ProtriptylineThe metabolism of Protriptyline can be increased when combined with Thiamylal.Approved
PSD502The risk or severity of adverse effects can be increased when Thiamylal is combined with PSD502.Investigational
PyridoxineThe metabolism of Thiamylal can be increased when combined with Pyridoxine.Approved, Nutraceutical, Vet Approved
PyrimethamineThe metabolism of Thiamylal can be decreased when combined with Pyrimethamine.Approved, Vet Approved
QuazepamThe risk or severity of adverse effects can be increased when Thiamylal is combined with Quazepam.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Quetiapine.Approved
QuinaprilThiamylal may increase the hypotensive activities of Quinapril.Approved, Investigational
QuinethazoneThiamylal may increase the orthostatic hypotensive activities of Quinethazone.Approved
QuinineThe metabolism of Thiamylal can be decreased when combined with Quinine.Approved
RacloprideThe risk or severity of adverse effects can be increased when Thiamylal is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Thiamylal is combined with Ramelteon.Approved, Investigational
RamiprilThiamylal may increase the hypotensive activities of Ramipril.Approved
RasagilineThiamylal may increase the hypotensive activities of Rasagiline.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Thiamylal.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Thiamylal.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Thiamylal.Approved
RifabutinThe metabolism of Thiamylal can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Thiamylal can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Thiamylal can be increased when combined with Rifapentine.Approved
RiociguatThiamylal may increase the hypotensive activities of Riociguat.Approved
RisedronateThe metabolism of Risedronate can be increased when combined with Thiamylal.Approved, Investigational
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Thiamylal.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Thiamylal is combined with Ritanserin.Investigational
RomifidineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Romifidine.Vet Approved
RopiniroleThiamylal may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Thiamylal.Approved
RotigotineThiamylal may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Thiamylal.Approved
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Thiamylal is combined with S-Ethylisothiourea.Experimental
SacubitrilThiamylal may increase the hypotensive activities of Sacubitril.Approved
Sage 547The risk or severity of adverse effects can be increased when Thiamylal is combined with Sage 547.Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Scopolamine.Approved
SecobarbitalThe metabolism of Thiamylal can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineThiamylal may increase the hypotensive activities of Selegiline.Approved, Investigational, Vet Approved
SertindoleThe risk or severity of adverse effects can be increased when Thiamylal is combined with Sertindole.Approved, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Thiamylal is combined with Sevoflurane.Approved, Vet Approved
SildenafilThe metabolism of Thiamylal can be decreased when combined with Sildenafil.Approved, Investigational
Sodium NitriteThiamylal may increase the hypotensive activities of Sodium Nitrite.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Thiamylal.Approved
SomatostatinThe risk or severity of adverse effects can be increased when Somatostatin is combined with Thiamylal.Approved
SorafenibThe metabolism of Thiamylal can be decreased when combined with Sorafenib.Approved, Investigational
SotalolThiamylal may increase the hypotensive activities of Sotalol.Approved
SpironolactoneThiamylal may increase the hypotensive activities of Spironolactone.Approved
StiripentolThe risk or severity of adverse effects can be increased when Thiamylal is combined with Stiripentol.Approved
StreptokinaseThiamylal may increase the hypotensive activities of Streptokinase.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Thiamylal.Approved, Investigational
SulfadiazineThe metabolism of Thiamylal can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Thiamylal can be decreased when combined with Sulfamethoxazole.Approved
SulfisoxazoleThe metabolism of Thiamylal can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Thiamylal.Approved
SuvorexantThiamylal may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
Synthetic Conjugated Estrogens, AThe therapeutic efficacy of Synthetic Conjugated Estrogens, A can be decreased when used in combination with Thiamylal.Approved
TamsulosinThiamylal may increase the hypotensive activities of Tamsulosin.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Thiamylal is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Thiamylal.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Thiamylal is combined with Tasimelteon.Approved
TelmisartanThiamylal may increase the hypotensive activities of Telmisartan.Approved, Investigational
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Thiamylal.Approved
TeniposideThe serum concentration of Teniposide can be decreased when it is combined with Thiamylal.Approved
TerazosinThiamylal may increase the hypotensive activities of Terazosin.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Tetracaine.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Thiamylal is combined with Tetrodotoxin.Investigational
ThalidomideThiamylal may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Thiamylal.Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Thiamylal.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Thiamylal.Approved
ThiothixeneThe risk or severity of adverse effects can be increased when Thiamylal is combined with Thiothixene.Approved
TiagabineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Tiagabine.Approved
TianeptineThe metabolism of Tianeptine can be increased when combined with Thiamylal.Approved
TiaprideThe risk or severity of adverse effects can be increased when Thiamylal is combined with Tiapride.Investigational
TicagrelorThe metabolism of Thiamylal can be decreased when combined with Ticagrelor.Approved
TiclopidineThe metabolism of Thiamylal can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Tiletamine.Vet Approved
TimololThiamylal may increase the hypotensive activities of Timolol.Approved
TizanidineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Tizanidine.Approved
TolazolineThiamylal may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolbutamideThe metabolism of Thiamylal can be decreased when combined with Tolbutamide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Thiamylal is combined with Tolcapone.Approved, Withdrawn
Tolfenamic AcidThe metabolism of Tolfenamic Acid can be increased when combined with Thiamylal.Approved
TopiramateThe risk or severity of adverse effects can be increased when Thiamylal is combined with Topiramate.Approved
TorasemideThiamylal may increase the hypotensive activities of Torasemide.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Thiamylal.Approved, Investigational
TrandolaprilThiamylal may increase the hypotensive activities of Trandolapril.Approved
TranilastThe metabolism of Tranilast can be increased when combined with Thiamylal.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Thiamylal.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Thiamylal.Approved, Investigational
TretinoinThiamylal may increase the hypotensive activities of Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThiamylal may increase the hypotensive activities of Triamterene.Approved
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Thiamylal.Approved
TrichlormethiazideThiamylal may increase the orthostatic hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Thiamylal.Approved
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Thiamylal.Approved, Vet Approved
TrimethoprimThe metabolism of Thiamylal can be decreased when combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe metabolism of Trimipramine can be increased when combined with Thiamylal.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Triprolidine.Approved
Uc1010The risk or severity of adverse effects can be increased when Thiamylal is combined with Uc1010.Investigational
UlipristalThe serum concentration of Ulipristal can be decreased when it is combined with Thiamylal.Approved
Valproic AcidThe serum concentration of Thiamylal can be increased when it is combined with Valproic Acid.Approved, Investigational
ValsartanThe metabolism of Thiamylal can be decreased when combined with Valsartan.Approved, Investigational
VenlafaxineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Venlafaxine.Approved
VerapamilThiamylal may increase the hypotensive activities of Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Thiamylal is combined with Vigabatrin.Approved
VinpocetineThe metabolism of Vinpocetine can be increased when combined with Thiamylal.Investigational
VoriconazoleThe serum concentration of Voriconazole can be decreased when it is combined with Thiamylal.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Vortioxetine.Approved
WarfarinThe metabolism of Warfarin can be increased when combined with Thiamylal.Approved
XylazineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Xylazine.Vet Approved
XylometazolineThe metabolism of Xylometazoline can be increased when combined with Thiamylal.Approved
ZafirlukastThe metabolism of Thiamylal can be decreased when combined with Zafirlukast.Approved, Investigational
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Thiamylal.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Thiamylal is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Thiamylal.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Thiamylal is combined with Zolazepam.Vet Approved
ZolpidemThiamylal may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Thiamylal is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Thiamylal is combined with Zopiclone.Approved
ZotepineThe risk or severity of adverse effects can be increased when Thiamylal is combined with Zotepine.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Thiamylal is combined with Zuclopenthixol.Approved, Investigational
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.5532
Blood Brain Barrier+0.9582
Caco-2 permeable-0.5361
P-glycoprotein substrateNon-substrate0.5169
P-glycoprotein inhibitor IInhibitor0.5544
P-glycoprotein inhibitor IINon-inhibitor0.9368
Renal organic cation transporterNon-inhibitor0.8887
CYP450 2C9 substrateNon-substrate0.8124
CYP450 2D6 substrateNon-substrate0.8589
CYP450 3A4 substrateNon-substrate0.7011
CYP450 1A2 substrateNon-inhibitor0.7869
CYP450 2C9 inhibitorNon-inhibitor0.5555
CYP450 2D6 inhibitorNon-inhibitor0.9131
CYP450 2C19 inhibitorNon-inhibitor0.6101
CYP450 3A4 inhibitorNon-inhibitor0.8138
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8282
Ames testNon AMES toxic0.6521
CarcinogenicityNon-carcinogens0.9047
BiodegradationNot ready biodegradable0.9974
Rat acute toxicity2.7058 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9781
hERG inhibition (predictor II)Non-inhibitor0.8205
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point132-133 °CPhysProp
water solubility49.4 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP3.23HANSCH,C ET AL. (1995)
logS-3.46ADME Research, USCD
pKa7.48SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility0.0506 mg/mLALOGPS
logP3.11ALOGPS
logP2.92ChemAxon
logS-3.7ALOGPS
pKa (Strongest Acidic)7.2ChemAxon
pKa (Strongest Basic)-3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area58.2 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity70.64 m3·mol-1ChemAxon
Polarizability26.75 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as thiobarbituric acid derivatives. These are organic compounds containing a 2-thioxodihydropyrimidine-4,6(1H,5H)-dione skeleton.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassDiazines
Sub ClassPyrimidines and pyrimidine derivatives
Direct ParentThiobarbituric acid derivatives
Alternative Parents
Substituents
  • Thiobarbiturate
  • 1,3-diazinane
  • Thiourea
  • Thiocarbonic acid derivative
  • Carboxamide group
  • Azacycle
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organosulfur compound
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Aliphatic heteromonocyclic compound
Molecular FrameworkAliphatic heteromonocyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By si...
Gene Name:
GABRA1
Uniprot ID:
P14867
Molecular Weight:
51801.395 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Sugimura M, Kitayama S, Morita K, Imai Y, Irifune M, Takarada T, Kawahara M, Dohi T: Effects of GABAergic agents on anesthesia induced by halothane, isoflurane, and thiamylal in mice. Pharmacol Biochem Behav. 2002 May;72(1-2):111-6. [PubMed:11900777 ]
  4. Whiting PJ: The GABAA receptor gene family: new opportunities for drug development. Curr Opin Drug Discov Devel. 2003 Sep;6(5):648-57. [PubMed:14579514 ]
  5. Mehta AK, Ticku MK: An update on GABAA receptors. Brain Res Brain Res Rev. 1999 Apr;29(2-3):196-217. [PubMed:10209232 ]
  6. Yamakura T, Bertaccini E, Trudell JR, Harris RA: Anesthetics and ion channels: molecular models and sites of action. Annu Rev Pharmacol Toxicol. 2001;41:23-51. [PubMed:11264449 ]
  7. Krasowski MD, Harrison NL: General anaesthetic actions on ligand-gated ion channels. Cell Mol Life Sci. 1999 Aug 15;55(10):1278-303. [PubMed:10487207 ]
  8. Grasshoff C, Netzhammer N, Schweizer J, Antkowiak B, Hentschke H: Depression of spinal network activity by thiopental: shift from phasic to tonic GABA(A) receptor-mediated inhibition. Neuropharmacology. 2008 Oct;55(5):793-802. doi: 10.1016/j.neuropharm.2008.06.026. Epub 2008 Jun 21. [PubMed:18619475 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Inward rectifier potassium channel activity
Specific Function:
This potassium channel is controlled by G proteins. Inward rectifier potassium channels are characterized by a greater tendency to allow potassium to flow into the cell rather than out of it. Their voltage dependence is regulated by the concentration of extracellular potassium; as external potassium is raised, the voltage range of the channel opening shifts to more positive voltages. The inward...
Gene Name:
KCNJ8
Uniprot ID:
Q15842
Molecular Weight:
47967.455 Da
References
  1. Eguchi S, Kawano T, Oshita S, Nakajo N: [Effects of propofol and thiamylal on nicorandil induced ATP-sensitive potassium channel activities in cultured rat aortic smooth muscle cells]. Masui. 2005 Apr;54(4):364-9. [PubMed:15852621 ]
  2. Kawano T, Oshita S, Takahashi A, Tsutsumi Y, Tomiyama Y, Kitahata H, Kuroda Y, Nakaya Y: Molecular mechanisms of the inhibitory effects of propofol and thiamylal on sarcolemmal adenosine triphosphate-sensitive potassium channels. Anesthesiology. 2004 Feb;100(2):338-46. [PubMed:14739809 ]
  3. Tsutsumi Y, Oshita S, Kitahata H, Kuroda Y, Kawano T, Nakaya Y: Blockade of adenosine triphosphate-sensitive potassium channels by thiamylal in rat ventricular myocytes. Anesthesiology. 2000 Apr;92(4):1154-9. [PubMed:10754636 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated potassium channel activity
Specific Function:
This receptor is controlled by G proteins. Inward rectifier potassium channels are characterized by a greater tendency to allow potassium to flow into the cell rather than out of it. Their voltage dependence is regulated by the concentration of extracellular potassium; as external potassium is raised, the voltage range of the channel opening shifts to more positive voltages. The inward rectific...
Gene Name:
KCNJ11
Uniprot ID:
Q14654
Molecular Weight:
43540.375 Da
References
  1. Kawano T, Oshita S, Takahashi A, Tsutsumi Y, Tomiyama Y, Kitahata H, Kuroda Y, Nakaya Y: Molecular mechanisms of the inhibitory effects of propofol and thiamylal on sarcolemmal adenosine triphosphate-sensitive potassium channels. Anesthesiology. 2004 Feb;100(2):338-46. [PubMed:14739809 ]
  2. Tsutsumi Y, Oshita S, Kitahata H, Kuroda Y, Kawano T, Nakaya Y: Blockade of adenosine triphosphate-sensitive potassium channels by thiamylal in rat ventricular myocytes. Anesthesiology. 2000 Apr;92(4):1154-9. [PubMed:10754636 ]
  3. Eguchi S, Kawano T, Oshita S, Nakajo N: [Effects of propofol and thiamylal on nicorandil induced ATP-sensitive potassium channel activities in cultured rat aortic smooth muscle cells]. Masui. 2005 Apr;54(4):364-9. [PubMed:15852621 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Sueyasu M, Fujito K, Shuto H, Mizokoshi T, Kataoka Y, Oishi R: Protein binding and the metabolism of thiamylal enantiomers in vitro. Anesth Analg. 2000 Sep;91(3):736-40. [PubMed:10960410 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23